Mitochondrial damage-associated molecular patterns as potential proinflammatory mediators in post-platelet transfusion adverse effects

Transfusion

Volumn 56, Issue 5, 2016, Pages 1201-1212

  Yasui, Kazuta ^a   Matsuyama, Nobuki ^a   Kuroishi, Ayumu ^a   Tani, Yoshihiko ^a   Furuta, Rika A ^a   Hirayama, Fumiya ^a  

^a Block Blood Centre   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL FACTOR; CD123 ANTIGEN; DAMAGE ASSOCIATED MOLECULAR PATTERN; FRESH FROZEN PLASMA; HLA ANTIBODY; HLA DR ANTIGEN; MITOCHONDRIAL DNA; UNCLASSIFIED DRUG; AUTACOID;

ANAPHYLAXIS; ARTICLE; BASOPHIL; BLOOD TRANSFUSION REACTION; CONTROLLED STUDY; DYSPNEA; ERYTHROCYTE; FEVER; HUMAN; HYPOTENSION; IN VITRO STUDY; MITOCHONDRION; MOLECULAR WEIGHT; MONOCYTE; NEUTROPHIL; NONHEMOLYTIC TRANSFUSION REACTION; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY BURST; ROOM TEMPERATURE; TRANSFUSION RELATED ACUTE LUNG INJURY; ADVERSE EFFECTS; BLOOD SAFETY; GENETICS; IMMUNITY; IMMUNOLOGY; JAPAN; THROMBOCYTE; THROMBOCYTE TRANSFUSION; TRANSFUSION REACTION; ULTRASTRUCTURE;

BASOPHILS; BLOOD PLATELETS; BLOOD SAFETY; DNA, MITOCHONDRIAL; HUMANS; IMMUNE SYSTEM PHENOMENA; INFLAMMATION MEDIATORS; JAPAN; MITOCHONDRIA; MONOCYTES; NEUTROPHILS; PLATELET TRANSFUSION; TRANSFUSION REACTION;

EID: 84966601395     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13535     Document Type: Article

References (54)

1. Klüter H, Bubel S, Kirchner H, et al., Febrile and allergic transfusion reactions after the transfusion of white cell-poor platelet preparations. Transfusion 1999; 39: 1179-84.
2. Pruss A, Kalus U, Radtke H, et al., Universal leukodepletion of blood components results in a significant reduction of febrile non-hemolytic but not allergic transfusion reactions. Transfus Apher Sci 2004; 30: 41-6.
3. Tamagawa-Mineoka R, Katoh N, Kishimoto S., Platelets play important roles in the late phase of the immediate hypersensitivity reaction. J Allergy Clin Immunol 2009; 123: 581-7.
4. Paglino JC, Pomper GJ, Fisch GS, et al., Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction. Transfusion 2004; 44: 16-24.
5. Muylle L, Joos M, Wouters E, et al., Increased tumor necrosis factor alpha (TNF alpha), interleukin 1, and interleukin 6 (IL-6) levels in the plasma of stored platelet concentrates: relationship between TNF alpha and IL-6 levels and febrile transfusion reactions. Transfusion 1993; 33: 195-9.
6. Muylle L, Wouters E, Peetermans ME., Febrile reactions to platelet transfusion: the effect of increased interleukin 6 levels in concentrates prepared by the platelet-rich plasma method. Transfusion 1996; 36: 886-90.
7. Heddle NM., Febrile nonhemolytic transfusion reactions to platelets. Curr Opin Hematol 1995; 2: 478-83.
8. Kato H, Uruma M, Okuyama Y, et al., Incidence of transfusion-related adverse reactions per patient reflects the potential risk of transfusion therapy in Japan. Am J Clin Pathol 2013; 140: 219-24.
9. Geiger TL, Howard SC., Acetaminophen and diphenhydramine premedication for allergic and febrile non-hemolytic transfusion reactions: good prophylaxis or bad practice? Transfus Med Rev 2007; 21: 1-12.
10. Cohn CS, Stubbs J, Schwartz J, et al., A comparison of adverse reaction rates for PAS C versus plasma platelet units. Transfusion 2014; 54: 1927-34.
11. Koda Y, Watanabe Y, Soejima M, et al., Simple PCR detection of haptoglobin gene deletion in anhaptoglobinemic patients with antihaptoglobin antibody that causes anaphylactic transfusion reactions. Blood 2000; 95: 1138-43.
12. Shimada E, Tadokoro K, Watanabe Y, et al., Anaphylactic transfusion reactions in haptoglobin-deficient patients with IgE and IgG haptoglobin antibodies. Transfusion 2002; 42: 766-73.
13. Schmidt MD, Taswell HF, Gleich GJ., Anaphylactic transfusion reactions associated with anti-IgA antibody. N Engl J Med 1969; 280: 188-93.
14. Sandler SG, Mallory D, Malamut D, et al., IgA anaphylactic transfusion reactions. Transfus Med Rev 1995; 1: 1-8.
15. Lambin P, Le Pennec PY, Hauptmann G, et al., Adverse transfusion reactions associated with a precipitating anti-C4 antibody of anti-Rodger specificity. Vox Sang 1984; 47: 242-9.
16. Jacobs JF, Baumert JL, Brons PP, et al., Anaphylaxis from passive transfer of peanut allergen in a blood product. N Engl J Med 2011; 364: 1981-2.
17. Nobuki M, Kazuta Y, Etsuko A, et al., The IgE-dependent pathway in allergic transfusion reactions: involvement of donor blood allergens other than plasma proteins. Int J Hematol. 2015; 102: 93-100.
18. Wadhwa M, Seghatchian MJ, Lubenko A, et al., Cytokine levels in platelet concentrates: quantitation by bioassays and immunoassays. Br J Haematol 1996; 93: 225-34.
19. Phipps RP, Kaufman J, Blumberg N., Platelet derived CD154 (CD40 ligand) and febrile responses to transfusion. Lancet 2001; 357: 2023-4.
20. Wakamoto S, Fujihara M, Kuzuma K, et al., Biologic activity of RANTES in apheresis PLT concentrates and its involvement in nonhemolytic transfusion reactions. Transfusion 2003; 43: 1038-46.
21. Sahler J, Spinelli S, Phipps R, et al., CD40 ligand (CD154) involvement in platelet transfusion reactions. Transfus Clin Biol 2012; 19: 98-103.
22. Vo TD, Cowles J, Heal JM, et al., Platelet washing to prevent febrile reactions to leucocyte-reduced transfusion. Transfus Med 2001; 11: 45-7.
23. Hamzeh-Cognasse H, Damien P, Nguyen KA, et al., Immune-reactive soluble OX40 ligand, soluble CD40 ligand, and interleukin-27 are simultaneously oversecreted in platelet components associated with acute transfusion reactions. Transfusion 2014; 54: 613-25.
24. Heddle NM, Klama L, Meyer R, et al., A randomized controlled trial comparing plasma removal with white cell reduction to prevent reactions to platelet. Transfusion 1999; 39: 231-8.
25. Matzinger P., Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
26. Pisetsky DS, Erlandsson-Harris H, Andersson U., High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease. Arthritis Res Ther 2008; 10: doi: 10.1186/ar2440
27. Klune JR, Dhupar R, Cardinal J, et al., HMGB1: endogenous danger signaling. Mol Med 2008; 14: 476-84.
28. Foell D, Wittkowski H, Vogl T, et al., S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007; 81: 28-37.
29. Vogl T, Tenbrock K, Ludwing S, et al., Mrp8 and Mrp14 are endogenous activations of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007; 13: 1042-9.
30. Wheeler DS, Chase MA, Senft AP, et al., Extracellular Hsp72, an endogenous DAMP, is released by virally infected airway epithelial cells and activates neutrophils via Toll-like receptor (TLR)-4. Respirat Res 2009; 10: 31. doi: 10.1186/1465-9921-10-31.
31. He RL, Zhou J, Hanson CZ, et al., Serum amyloid a induces G-CSF expression and neutrophilia via Toll-like receptor 2. Blood 2009; 113: 429-37.
32. Sandri S, Rodriguez D, Gomes E, et al., Is serum amyloid A an endogenous TLR4 agonist? J Leukoc Biol 2008; 83: 1174-80.
33. Zhang Q, Raoof M, Chen Y, et al., Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010; 464: 104-7.
34. Sun S, Sursal T, Adibnia Y, et al., Mitochondria DAMPs increase endothelial permeability through neutrophil dependent and independent pathways. PLoS One 2013; 8: e59989.
35. Rabiet MJ, Huet E, Boulay F., Human mitochondria-derived N-formylated peptides are novel agonists equally activate on FPR and FPRL1, while Listeria monocytogenes-derived peptides preferentially activate FPR. Eur J Immunol 2005; 35: 2486-95.
36. Wenceslau CF, McCarthy CG, Szasz T, et al., Mitochondrial N-formyl peptides induce cardiovascular collapse and sepsis-like syndrome. Am J Pathol Heart Circ Physiol 2015; 308: H768-77. doi: 10.1152/ajpheart.00779.2014.
37. Boudreau LH, Duchez AC, Cloutier N, et al., Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote inflammation. Blood 2014; 124: 2173-83.
38. Setzer B, Lebrecht D, Walker UA., Pyrimidine nucleoside depletion sensitizes to the mitochondrial hepatotoxicity of the reverse transcriptase inhibitor stavudine. Am J Pathol 2008; 172: 681-90.
39. Meisel SR, Shapiro H, Radnay J, et al., Increased expression of neutrophil and monocyte adhesion molecules LFA-1 and Mac-1 and their ligand ICAM-1 and VLA-4 throughout the acute phase of myocardial infarction: possible implications for leukocyte aggregation and microvascular plugging. J Am Coll Cardiol 1998; 31: 120-5.
40. Yasui K, Furuta RA, Matsuyama N, et al., Possible involvement of heparin-binding protein in transfusion-related acute lung injury. Transfusion 2008; 48: 978-87.
41. Matsuyama N, Hirayama F, Wakamoto S, et al., Application of the basophil activation test in the analysis of allergic transfusion reactions. Transfus Med 2009; 19: 274-7.
42. Hirayama F., Recent advance in laboratory assays for nonhemolytic transfusion reactions. Transfusion 2010; 50: 252-63.
43. 2+ influx-inducing activity toward mast cells in pretransfusion sera from patients who developed transfusion-related adverse reactions. Transfusion 2009; 49: 1754-61.
44. Kappelmayer J, Beke DI, Vida A, et al., Distinct effects of Re- and S-forms of LPS on modulating platelet activation. J Thromb Haemost 2013; 11: 775-8.
45. Yasui K, Angata T, Matsuyama N, et al., Detection of anti-Siglec-14 alloantibodies in blood components implicated in nonhaemolytic transfusion reactions. Br J Haematol 2011; 153: 794-6.
46. Hashimoto S, Nakajima F, Kamada H, et al., Relationship of donor HLA antibody strength to the development of transfusion-related acute lung injury. Transfusion 2010; 50: 2582-91.
47. Kaufman RM, Assmann SF, Triulzi DJ, et al., Transfusion-related adverse events in the platelet dose study. Transfusion 2015; 55: 144-53.
48. Nguyen KA, Hamzeh-Cognasse H, Sebban M, et al., A computerized prediction model of hazardous inflammatory platelet transfusion outcomes. PLoS One 2014; 9: e97082.
49. Tanaka S, Hayashi T, Tani Y, et al., Removal by adsorbent beads of biological response modifiers released from platelets, accumulated during storage, and potentially associated with platelet transfusion reactions. Transfusion 2010; 50: 1096-105.
50. Doescher A, Petershofen EK, Hertenstein B, et al., Platelet recovery and survival measured in patients by quantitative polymerase chain reaction of mitochondria DNA. Transfusion 2015; 55: 55-63.
51. Bakkour S, Chafets DM, Wen L, et al., Development of a mitochondria DNA real-time polymerase chain reaction assay for quality control of pathogen reduction with riboflavin and ultraviolet light. Vox Sang 2014; 107: 351-9.
52. Simmons JD, Lee YL, Mulekar S, et al., Elevated levels of plasma mitochondria DNA DAMPs are linked to clinical outcome in severely injured human subjects. Ann Surg 2013; 258: 591-6.
53. Lee YL, King MB, Gonzalez RP, et al., Blood transfusion products contain mitochondria DNA damage-associated molecular patterns: a potential effector of transfusion-related acute lung injury. J Surg Res 2014; 191: 286-9.
54. Nakahira K, Kyung SY, Rogers AJ, et al., Circulating mitochondria DNA in patients in the ICU as a marker of mortality: derivation and validation. PLoS Med 2013; 10: e1001577.